Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Disease-modifying therapies such as transthyretin (TTR) gene-silencing drugs and TTR tetramer stabilizers have been developed for hereditary transthyretin (ATTR) amyloidosis, a major type of autosomal dominant hereditary amyloidosis. Recently, a second-generation TTR gene-silencing drug, vutrisiran, was approved for treating patients with hereditary ATTR amyloidosis in Japan. This new drug significantly reduced the patient's physical burden.

Citation

Mitsuharu Ueda. Therapeutic Strategies for Hereditary Transthyretin Amyloidosis]. Brain and nerve = Shinkei kenkyu no shinpo. 2023 May;75(5):539-541

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 37194527

View Full Text